Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 11:16:2683-2693.
doi: 10.2147/DDDT.S366622. eCollection 2022.

Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity

Zhaoqiang Dong  1 , Yuzhen Wang  2 , Jing Guo  3 , Chuan Tian  4 , Wengu Pan  4 , Hongwei Wang  4 , Jieke Yan  4
Affiliations

Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity

Zhaoqiang Dong et al. Drug Des Devel Ther. .

Abstract

Objective: To evaluate the prostate cancer therapy efficiency of the synergistic combination docetaxel (DTX) and formononetin (FMN) in one nano-sized drug delivery system. Hyaluronic acid (HA) and epidermal growth factor receptor-targeted peptide (GE11) dual ligands were applied to modify the nano-systems.

Methods: In this study, GE11-modified nanoparticles (GE-NPs) were applied for the loading of DTX, and HA-decorated NPs (HA-NPs) were used to encapsulate FMN. HA and GE11 dual ligand-modified binary nanoparticles (HAGE-DTX/FMN-NPs) were constructed by the self-assembling of GE-NPs and HA-NPs. The anti-PCa ability of the system was evaluated in vitro on PC-3 human prostate carcinoma cells (PC3 cells) and in vivo on PC3 tumor-bearing mice in comparison with single NPs and free drugs formulations.

Results: HA/GE-DTX/FMN-NPs were nano-sized particles with smaller particles coating on the inner core and achieved a size of 189.5 nm. HA/GE-DTX/FMN-NPs showed a cellular uptake efficiency of 59.6%, and a more efficient inhibition effect on PC3 cells compared with single ligand-modified NPs and free drugs. HA/GE-DTX/FMN-NPs showed significantly higher tumor inhibition efficiency than their single drug-loaded counterparts and free drugs.

Conclusion: HA/GE-DTX/FMN-NPs have a synergistic anti-tumor effect and also could the reduce unexpected side effects during the cancer therapy. It could be used as a promising anti-PCa system.

Keywords: binary nanoparticles; docetaxel; epidermal growth factor receptor; formononetin; hyaluronic acid; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Scheme graphs and TEM images of GE-DTX-NPs (A), HA-FMN-NPs (B), and HA/GE-DTX/FMN-NPs (C).
Figure 2
Figure 2
Stability of NPs during storage at 4°C (A), and in the presence of fetal bovine serum (FBS, 10%, v/v) at 37°C for 72 h (B). Data are presented as means ± standard deviation (n=3).
Figure 3
Figure 3
In vitro DTX (A) and FMN (B) release performed using dialysis method. Data are presented as means ± standard deviation (n=3).
Figure 4
Figure 4
Cellular uptake efficiency of the coumarin 6-loaded NPs in PC3 cells: fluorescence images (A) and quantified by flow cytometer (B). Bars stand for 50 μm. Data are presented as means ± standard deviation (n=3). *P < 0.05.
Figure 5
Figure 5
In vitro cytotoxicity of different formulations on PC3 cells (A) and RWPE-1 cells (B). CI values versus Fa at different DTX to FMN ratios (C). Data are presented as means ± standard deviation (n=3). *P < 0.05.
Figure 6
Figure 6
In vivo anti-tumor efficacy of different formulations in mice bearing human prostate cancer model: Tumor volumes and images. Data are presented as means ± standard deviation (n=8). *P < 0.05.
Figure 7
Figure 7
In vivo DTX (A) and FMN (B) tissue distribution. Data are presented as means ± standard deviation (n=8). *P < 0.05.
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492 - DOI - PubMed
    1. Cassell A, Yunusa B, Jalloh M, et al. Management of advanced and metastatic prostate cancer: a need for a sub-saharan guideline. J Oncol. 2019;2019:1785428. doi: 10.1155/2019/1785428 - DOI - PMC - PubMed
    1. Horwich A, Parker C, Kataja V; ESMO Guidelines Working Group. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):76–78. doi: 10.1093/annonc/mdp135 - DOI - PubMed
    1. National Comprehensive Cancer Network: NCCN clinical prastice guidelines in oncology (NCCN Guidelines®): prostate cancer V.2.2021. National Comprehensive Cancer Network, Inc. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459. Accessed July 29, 2022.
    1. Oudard S. TROPIC: phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011;7(4):497–506. doi: 10.2217/fon.11.23 - DOI - PubMed